Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm

A Prospective Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm

To acquire, amplify, digitize, and record atrial intracardiac electrophysiology signals during cardiac electrophysiology studies for the treatment of persistent atrial fibrillation and to use the recorded data to test the performance of an signal complexity visualization algorithm.

Study Overview

• Status: Completed
• Conditions: Cardiac Arrhythmia; Persistent Atrial Fibrillation
• Intervention / Treatment: Procedure: Cardiac Ablation for the treatment of persistent Atrial Fibrillation

Detailed Description

A prospective, single-center, pilot study using the CathVision ECGenius® system and the Ablation Impact Analyzer software in radiofrequency (RF) ablation procedures.

Subjects with persistent atrial fibrillation who are indicated to undergo an RF ablation to treat persistent AF may be enrolled in the Study.

Intracardiac signals will be passively recorded using the investigational ECGenius® System in parallel with the commercial (FDA Approved) EP Workmate, Abbott Inc. EP recording system. The investigational device will not be used for direct clinical care decisions or therapy.

The CathVision ECGenius system allows physicians and users to record intracardiac electrograms during human electrophysiological studies including treatments for atrial fibrillation and atrial tachycardias. Improvements to the first-generation system are in development and include software features and algorithms for further analysis and description of signals to improve the clinical utility of the recorded signals. These new algorithms and software features require leveraging clinical use data as part of the development and iteration process.

This study will allow the evaluation of algorithms for advanced signal analysis in a low-risk clinical setting by recording raw electrocardiograms during standard of care cardiac mapping and ablation treatments for tachyarrhythmias, specifically atrial tachycardias and atrial fibrillation. The data will be recorded by a conventional market-approved EP recording system and on a parallel investigational CathVision ECGenius system for subsequent offline prototype analysis. Information from the investigational system and algorithms will not be available to the physician during the treatment and will have no diagnostic or therapeutic impact on the clinical case.

The validation of the automated algorithm will be performed offline.

• Study Type: Observational
• Enrollment (Actual): 37

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • NYU Langone Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients already referred to undergo a cardiac ablation as treatment for persistent atrial fibrillation

Description

Inclusion Criteria:

Eligible patients will meet all of the following inclusion criteria:

1. Patients scheduled for RF ablation indicated by the investigator for the treatment of persistent atrial fibrillation.
2. Male or female ≥ 21 years of age.
3. Able and willing to provide written informed consent prior to any clinical investigation related procedure.

Exclusion Criteria:

Eligible patients will not meet any of the following exclusion criteria:

1. Current participation in another investigational drug or device study that interferes with this study.
2. Patients who, in the opinion of the investigator, are not candidates for this study.
3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
4. Life expectancy less than 12 month, in the opinion of the Investigator.
5. Patients who are considered part of any vulnerable population.
6. Patient is a prisoner.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Persistent AF Arm; Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation	Procedure: Cardiac Ablation for the treatment of persistent Atrial Fibrillation; Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ability to Collect CS Data	Data collected during the study will be used to test a signal complexity visualization algorithm. The primary outcome measure was the ability of the system to achieve this in each patient.	One day - day of procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of AF Cycle Length	Data collected during the study will be used to test an AF cycle length algorithm	At the start of the procedure from the insertion of the CS catheter to the first ablation

Collaborators and Investigators

• Sponsor: CathVision ApS
• Collaborators: Medicept Inc
• Investigators: Principal Investigator: Larry Jacob, MD, NYU Langone

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2022
• Primary Completion (Actual): October 30, 2023
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: June 17, 2022
• First Submitted That Met QC Criteria: July 12, 2022
• First Posted (Actual): July 14, 2022

Study Record Updates

• Last Update Posted (Estimated): December 16, 2025
• Last Update Submitted That Met QC Criteria: November 28, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Pathological Conditions, Signs and Symptoms; Atrial Fibrillation; Arrhythmias, Cardiac; Therapeutics; Surgical Procedures, Operative; Ablation Techniques; Radiofrequency Ablation; Radiofrequency Therapy; Catheter Ablation
• Other Study ID Numbers: CVAR-00001-A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No